Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give written consent to participate
• People aged 18 to 75 years old, of any gender
• People who have been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer) confirmed by laboratory testing, had surgery to remove it that met certain guidelines, and have no sign of the cancer spreading to distant parts of the body on imaging scans
• People whose post-surgery pathology report showed the tumour was removed with clear or close margins (known as R0 or R1 resection)
• People whose tumour tests positive for a protein called EGFR, measured by a laboratory test on tumour tissue
• People who have had their tumour tested for a gene called KRAS and a protein called CDX-2 before starting the trial (these results are used for later analysis only)
• People whose blood test results show their bone marrow, liver, and kidneys are functioning at an adequate level, meeting specific thresholds set by the trial (confirm with trial site for exact values)
• People with a general health and activity level rated as 0 or 1 on the ECOG scale, meaning they are fully active or have only minor limitations in physical activity
• People whose doctors expect them to survive at least 3 months after surgery
• People who are able to have children and are willing to use contraception throughout the study period

Who may not be able to join:

• People who received chemotherapy, radiation, or other cancer treatments for their pancreatic cancer before surgery
• People with a history of another cancer, except for certain skin cancers or early-stage cervical changes that have been fully treated and cured
• People with certain serious health conditions, including severe heart failure, unstable chest pain, poorly controlled heart rhythm problems, uncontrolled high blood pressure, active infections, unmanageable diabetes, fluid build-up in the chest or abdomen requiring drainage, severe liver-related high blood pressure, blockage of the stomach outlet, or breathing difficulties
• People who experienced serious complications after surgery — such as bleeding, pancreatic leakage, stomach blockage, abdominal infection, or bile leakage — that would prevent them from starting treatment within 12 weeks of surgery
• People whose CA19-9 blood marker level was above 180 U/ml within 21 days before starting treatment
• People with a known allergy to any of the medications or their ingredients used in this trial
• People with a known HIV, syphilis, or active hepatitis B or C infection
• People whom the trial doctors consider unsuitable for participation for other medical reasons

Important: Always verify eligibility with the trial site directly before applying.